



Breaking Ground: 2025 Milestones in Cushing Syndrome and Looking Forward to 2026

ACC. Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study. Available at: <https://accscientificsession.acc.org/Plan-Your-Program/Education-Sessions/Late-Breakers>. Accessed March 6, 2026.

Aresta C, Soranna D, Giovanelli L, et al. When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. *Endocr Pract*. 2021;27(12):1216-1224.

Bancos I, Geer EB, Castinetti F, et al. 7790 A Non-interventional, Multinational, Phase IV Study to Evaluate the Long-Term Safety and Efficacy of Osilodrostat in Patients with Endogenous Cushing's Syndrome (LINC 6): 1-Year Real-World Interim Analysis. *J Endocr Soc*. 2024;8(Supplement_1):1098.

Bancos I, Castinetti F, Geer EB, et al. SUN-054 Long-Term, Real-World, Safety and Effectiveness of Osilodrostat In Patients With Pituitary and Non-Pituitary Cushing's Syndrome: 2-Year Interim Data From LINC 6. *J Endocr Soc*. 2025;9(Suppl 1):1639.

Buse JB, Kahn SE, Aroda VR, et al; CATALYST Investigators. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. *Diabetes Care*. 2025;48(12):2012-2020.

Elenius H, McGlotten R, Moore C, et al. 9330 Atumelnant (crn04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With Acth-Dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-Label Study. *J Endocr Soc*. 2024;8(Suppl 1):114.

Fallo F, Paoletta A, Tona F, Boscaro M, Sonino N. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. *J Intern Med*. 1993;234(6):595-598.

Fleseriu M, Badiu CP, Bancos I, et al. OR12-04 Clotriben, an 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, vs Placebo in a Phase II Trial for ACTH-dependent Cushing's Syndrome (RESCUE). *J Endocr Soc*. 2025;9(Suppl 1):1471.

Fleseriu M, Badiu CP, Bancos I, et al. Clotriben inhibits 11 β -hydroxysteroid dehydrogenase type 1 and improves ACTH-dependent Cushing's syndrome compared with placebo in a phase II trial (RESCUE). *Endocrine Abstracts*. 2025;110:RC4.3.

Jabbour S, Arnaldi G, Auchus R, et al. Relacorilant on Blood Pressure and Antihypertensive Medication Burden in Patients With Hypercortisolism and Hypertension: Results From the GRACE Study. Poster Presented at Heart in Diabetes June 6-8, 2025. Abstract 0097.

Jusufović S, Halilčević A, Jusufović R, et al. The Prevalence of Hypercortisolism in Patients with Type 2 Diabetes and Microvascular Complications: A Prospective Observational Case-Control Study. *Clinical Diabetology*. 2024;13(5):246-253.

Pivonello R, Arnaldi G, Auchus RJ, et al; GRACE Study Investigators. Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. *Lancet Diabetes Endocrinol*. 2026:S2213-8587(25):00362-00366.

Pivonello R, Arnaldi G, Auchus R, et al. Medical treatment of hypercortisolism with relacorilant: Final results of the phase 3 GRACE study. *Endocrine Abstracts*. 2025;110:P69.

Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing's syndrome: state of the art. *Lancet Diabetes Endocrinol*. 2016;4(7):611-629.